Product nameAnti-Met (c-Met) antibody
See all Met (c-Met) primary antibodies
DescriptionRabbit polyclonal to Met (c-Met)
Tested applicationsSuitable for: IHC-P, WB, ICC/IFmore details
Species reactivityReacts with: Human
Synthetic peptide, corresponding to a region witin C terminal amino acids 1329-1390 of Human Met (c-Met).
- A431, H1299, HepG2 or Raji cell lines; HeLa S3 whole cell lysate; Cal27 xenograft tissue
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab137654 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/100 - 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. Suggested antigen retrieval using heat mediated 10mM citrate buffer (pH6.0) or Tris-EDTA buffer (pH8.0).|
|WB||1/500 - 1/3000. Predicted molecular weight: 158 kDa.|
|ICC/IF||Use at an assay dependent concentration. PubMed: 23818604|
FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Information by UniProt
- AUTS9 antibody
- c met antibody
- D249 antibody
All lanes : Anti-Met (c-Met) antibody (ab137654) at 1/1000 dilution
Lane 1 : WT HeLa cell extract
Lane 2 : Met (c-Met) Knockout HeLa cell extracts
Lysates/proteins at 30 µg per lane.
All lanes : HRP-conjugated anti-rabbit IgG
Predicted band size: 158 kDa
Observed band size: 70 kDa why is the actual band size different from the predicted?
Anti-Met (c-Met) antibody (ab137654) at 1/1000 dilution + Hela S3 whole cell lysate at 30 µg
Predicted band size: 158 kDa
5% SDS PAGE
Immunohistochemical analysis of paraffin embedded Cal27 xenograft, labelling Met (c-Met) with ab137654 at 1/100 dilution.
This product has been referenced in:
- Endo Y et al. T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways. MAbs 10:1003-1017 (2018). Read more (PubMed: 30130447) »
- Gerdes MJ et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 110:11982-7 (2013). ICC/IF ; Human . Read more (PubMed: 23818604) »